Pale Stools at Seven Weeks: Cholangiogram Now or a HIDA Scan Later
A 7-week-old girl, born at 36 weeks, is referred for jaundice that has persisted since week 2. She is exclusively breastfed and gaining about 15 g/day. At the 2-week visit her mother was told this was breast milk jaundice. Today the stools are pale yellow to putty-colored and the urine is dark. She has scleral icterus without hepatomegaly; the spleen tip is 1 cm below the costal margin. Total bilirubin 9.8 mg/dL, direct 6.4 mg/dL, GGT 512 U/L, ALT 88 U/L, albumin 3.8 g/dL, INR 1.1, platelets 310,000/µL. Ultrasound reports a nonvisualized gallbladder and a triangular cord sign. The surgical team can operate tomorrow. The nuclear medicine HIDA scan has a 12-day wait. The family asks whether they can simply wait and repeat blood tests.
1. What is the next best step now, and why is the HIDA scan the wrong test for this infant?
Read the worked answer
Proceed to operative cholangiogram with liver biopsy under the same anesthetic, prepared to perform a Kasai portoenterostomy if biliary atresia is confirmed.
Reasoning:
- Conjugated hyperbilirubinemia at 7 weeks with putty-colored stools, GGT 512 U/L, a nonvisualized gallbladder, and a triangular cord sign is biliary atresia until proven otherwise. The diagnosis is established by intraoperative cholangiogram, not by imaging alone.
- A HIDA scan cannot separate biliary atresia from severe cholestasis of any cause when the direct bilirubin is this high; non-excretion is expected and nondiagnostic. A 12-day delay buys a low-yield test while the Kasai window closes. Native liver survival falls with each week beyond 60 days.
- While awaiting surgery: MCT-enriched formula, fat-soluble vitamins A, D, E, K, ursodiol 10–20 mg/kg/day, vitamin K 1 mg IM if the INR is prolonged, and a stool color card for the family.
- The family should be told plainly that this is a time-critical operation, that a cholangiogram at surgery can confirm or exclude atresia, and that Kasai is performed immediately if atresia is found.
2. The cholangiogram shows patent but thread-like extrahepatic ducts with bile flow, so the surgeon biopsies instead of performing a Kasai. How do you interpret this, what does the GGT of 512 U/L tell you, and what is your workup?
Read the worked answer
A patent extrahepatic biliary tree excludes biliary atresia but does not exclude biliary hypoplasia or duct paucity. Thread-like ducts are typical of Alagille syndrome, where the extrahepatic tree is patent but the intrahepatic ducts are sparse.
What the GGT means:
- A high GGT (512 U/L) is consistent with Alagille syndrome, biliary atresia, or MDR3 disease. It points away from the GGT-normal disorders: PFIC1 and PFIC2, the primary bile acid synthesis defects, and TPN-associated cholestasis. If the GGT had been normal, the mass-spectrometry urine bile acid profile and a PFIC/ bile acid synthesis gene panel would be the priority.
- Do not rely on the operative appearance alone; hypoplastic ducts can look abnormal yet be patent.
Workup:
- Liver biopsy: degree of duct paucity (count ducts per portal tract), fibrosis, and ductular reaction.
- JAG1 sequencing plus deletion analysis for the 20p12 microdeletion; NOTCH2 if negative. Send a cholestasis gene panel in parallel.
- Screen the extrahepatic features: echocardiogram and lung exam for peripheral pulmonary stenosis, slit-lamp for posterior embryotoxon, spine films for butterfly vertebrae, renal ultrasound, and lipid profile for xanthomas.
- Manage pruritus, fat-soluble vitamins, and nutrition; monitor for portal hypertension. Roughly 20–40% eventually need transplant, so follow spleen size, platelets, and surveillance endoscopy.
3. Assume the cholangiogram confirmed biliary atresia and a Kasai was done at 55 days. What postoperative milestones determine whether this child should be listed for transplant, and when?
Read the worked answer
The single most important milestone is clearance of jaundice: a total bilirubin under 1 mg/dL within 3 months of Kasai predicts native liver survival of roughly 70–80% at 10 years. Failure to clear jaundice by 3 months is itself a listing trigger and should prompt referral, not another year of observation.
Other triggers:
- Recurrent cholangitis, especially with fever and rising bilirubin, requiring admission and antibiotics; repeated episodes are a poor prognostic sign.
- Portal hypertension: splenomegaly with thrombocytopenia, varices on endoscopy, ascites, or growth failure.
- Synthetic dysfunction: rising INR, falling albumin, or poor weight gain despite adequate calories.
- Screening for hepatopulmonary syndrome and portopulmonary hypertension before listing.
Practical points:
- Do not wait for end-stage decompensation. A child whose Kasai has failed should be listed while relatively well; PELD includes bilirubin, albumin, INR, age under 1 year, and growth failure below −2 SD, so a well-compensated child can score deceptively low.
- Identify a potential living donor early; living-donor transplant can shorten the wait substantially for a small infant.
- The family should hear now that transplant is likely, so evaluation is not an emergency room conversation later.